Mogam Biotechnology Research Institute

The Green Cross Corporation

Mogam Institute for Biomedical Research

Yonsei University

Medigenebio Corporation

Kyuhyun Lee

Seongtae Yun

Eui-Cheol Jo

Daekyung Koh

Hyeon Bum Lee

Hong-Kyu Lee

Sujeong Kim

Soongyu Choi

Hyung-Kwon Lim

Mijung Lee

Dong-Sik Kim

Eun Jung Song

Young Seoub Park

Eun-Hee Lee

Kisu Kim

Jongwha Won

Jae Hyun Park

Yong-Chul Kim

Chae-Ok Yun

Thong-Gyu Jin

Doo-Hong Park

Jae Chan Park

Miyoung Oh

Mihee Hwang

Yeup Yoon

Han-Yeul Byun

Torayuki Okuyama

In-Young Jang

Jang-Seong Kim

Jin-Hyung Ahn

Ho-Jeong Lee

Byoung-Ju Lee

Jin-Wook Seo

Seong-Tae Yun

The present invention provides, among other things, compositions and methods for CNS delivery of Idursulfase-beta, a human recombinant iduronate-2-sulfatase protein, for effective treatment of Hunter Syndrome. The compositions and methods provided by the present invention effectively reduce symptoms not only in brain and spinal cord but also in peripheral tissues including heart, liver, spleen, lung, and kidney.

Methods and compositions for treating hunter syndrome

The present invention relates to an antibody specifically bound to mesothelin (MSLN), a nucleic acid encoding the antibody, a vector and a host cell including the nucleic acid, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumor including the antibody as an active ingredient. The antibody specifically bound to the mesothelin according to the present invention has high affinity and specificity to an antigen, such that it is possible to develop an antibody effectively usable for treatment or diagnosis of cancer or tumor diseases.

Anti-mesothelin antibody and composition comprising the same

The present invention relates to an antibody specifically binding to glypican 3 (GPC3), a nucleic acid encoding the antibody, a vector and a host cell containing the nucleic acid, a method of preparing the antibody, and a pharmaceutical composition for treating cancer or tumor, containing the antibody as an active ingredient. The antibody specifically binding to glypican 3 according to the present invention may be effectively used to treat cancer or tumor, particularly, hepatocellular carcinoma due to high affinity and specificity to glypican 3.

Anti-glypican 3 antibody and pharmaceutical composition containing the same

Novel hexon isolated from simian adenovirus serotype 19 encoded in the polynucleotide defined as SEQ ID NO: 3, hepervariable region thereof, chimeric adenovirus comprising the same, and therapeutic use thereof provides a solution to the problem of safety and effective systemic treatment for developing gene therapeutic agents using adenovirus.

Hexon isolated from simian adenovirus serotype 19, hypervariable region thereof and chimeric adenovirus using the same

Provided are tumor-specific promoters, oncolytic virus vectors and a pharmaceutical composition comprising the virus vector. The virus vector comprising the novel tumor-specific promoter shows excellent oncolytic effects on tumor cells, and thus it is useful for treating a cancer.

Tumor specific promoter and oncolytic virus vector comprising the same

Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc.

Expression vector suitable for expression of a coding sequence for gene therapy

Expression vector for gene therapy

Growing community of inventors

Yongin-si, South Korea

Kyuhyun Lee